Cat. No.: DIA-0243031
Product Information | |
---|---|
CAS No. | 1425945-63-6 |
Formula | C17H11Cl2N5OS |
Molecular Weight | 404.27 |
SMILES | N=C(C(S1)=NC2=C1C3=C(NC4=CC=C(Cl)C=C4Cl)N=CN=C3C=C2)OC |
Target | DYRK, CDK, GSK-3 |
Product Description | EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC50s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively. |
Format & Storage | |
---|---|
Format | Solid |
Color | Off-white to yellow |
Purity | 98.12% |
Shipping | Room temperature in the continental U.S. Other areas may vary. |
Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 6 months; -20°C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.